Repligen to Report Fourth Quarter and Full Year 2019 Financial Results
February 06 2020 - 7:30AM
Repligen Corporation (NASDAQ:RGEN) today announced that the Company
will report its fourth quarter and full year 2019 financial results
on Thursday, February 20, 2020. The Company will issue a press
release before the market opens and will host a conference call at
8:30 a.m. EST to discuss business updates and financial results for
the three- and twelve-month reporting periods ended December 31,
2019. The conference call will be accessible by dialing
toll-free (844) 701-1063 for domestic callers and (412) 317-5487
for international callers. No passcode is required for the live
call. In addition, a webcast will be accessible via the Investor
Relations section of the Company’s website. Both the conference
call and webcast will be archived for a period of time following
the live event. The replay dial-in numbers are (877) 344-7529 for
callers in the U.S., (855) 669-9658 for callers in Canada and (412)
317-0088 for international callers. Replay listeners must provide
the passcode 10137263.
About Repligen
CorporationRepligen Corporation is a global life sciences
company that develops and commercializes highly innovative
bioprocessing technologies and systems that increase efficiencies
in the process of manufacturing biological drugs. We are inspiring
advances in bioprocessing for the customers we serve; primarily
biopharmaceutical drug developers and contract development and
manufacturing organizations (CDMO’s) worldwide. Our corporate
headquarters are located in Waltham, MA (USA), and we have
additional administrative and manufacturing operations in
Marlborough, MA; Bridgewater, NJ; Rancho Dominguez, CA; Lund,
Sweden; Breda, The Netherlands and Ravensburg, Germany. This
press release may contain forward-looking statements within the
meaning of the federal securities laws. Investors are cautioned
that statements in this press release which are not strictly
historical statements including, without limitation, statements
identified by words like “believe,” “expect,” “may,” “will,”
“should,” “seek,” or “could” and similar expressions, constitute
forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated,
including risks discussed from time to time in our filings with the
Securities and Exchange Commission. We expressly disclaim any
responsibility to update any forward-looking statements, except as
required by law.
Repligen
Contact: Sondra S. NewmanGlobal Head of Investor
Relations(781) 419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024